Month: August 2024

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024 Achieved alignment with Food and Drug Administration (FDA) on the company’s proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Completed out-licensing of pediatric lysosomal storage disease programs to GEMMA Biotherapeutics Strong balance sheet to support continued execution, with cash runway to fund operations extended to the end of Q2 2026 PHILADELPHIA, Aug. 08, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients...

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, August 8, 2024, at 8:30 am ET GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. “During the second quarter, we continued to highlight the scientific evidence supporting the robust therapeutic potential of pemvidutide in metabolic diseases,” said...

Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

Completed initial public offering, raising $174.4 million in gross proceeds, including full exercise of the underwriters’ option to purchase additional shares and a concurrent private placement, to fund clinical development of precision neuroscience pipeline Phase 2a trial of RAP-219 in focal epilepsy initiation on track, with topline data expected in mid-2025 On track to begin two additional proof of concept clinical trials of RAP-219 in patients with peripheral neuropathic pain in 2H 2024, and patients with bipolar disorder in 2025 Terry-Ann Burrell, who was recently appointed as vice chairman of investment banking at JPMorgan, will transition off the Board of Directors of Rapport following the Company’s Form 10-Q filing Ended the quarter with $336.1 million in cash, cash equivalents, and short-term investments, excluding restricted...

Americold Announces Second Quarter 2024 Results

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

Achieves Double Digit Same Store NOI Growth, Record Services Margins for a Second Consecutive Quarter and Raises Full Year Earnings Guidance ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) — Americold Realty Trust, Inc. (NYSE: COLD) (the “Company”), a global leader in temperature-controlled logistics, real estate, and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced financial and operating results for the second quarter ended June 30, 2024. George Chappelle, Chief Executive Officer of Americold Realty Trust, stated, “As the operational and financial results of the second quarter highlight, it’s been another great quarter for organic growth at Americold as we produced double digit year-over-year growth in Global Warehouse Same Store NOI,...

Lifetime Brands, Inc. Reports Second Quarter 2024 Financial Results

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

Declares Regular Quarterly DividendReiterates Full Year 2024 Outlook GARDEN CITY, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) — Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of branded consumer products used in the home, today reported its financial results for the quarter ended June 30, 2024. Rob Kay, Lifetime’s Chief Executive Officer, commented, “Our results for the second quarter were in line with our expectations even though macroeconomic pressures led to weakened demand across end markets. Despite these challenges, we were able to grow share across the majority of our categories, deliver growth in our e-commerce channel in our core U.S. market and expand our gross margins, a testament to the success of our operating strategy and we remain well positioned for resilient...

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

On track for potential US commercial launch of obe-cel; PDUFA date November 16, 2024 Longer follow up and subset analyses from pivotal FELIX Phase 2 data presented at ASCO and EHA; majority of responders showed durable responses; 40% of patients in ongoing remission without subsequent stem cell transplant (SCT) or other intervention A Market Authorization Application (MAA) for obe-cel in relapsed/refractory r/r adult B-cell Acute Lymphoblastic Leukemia (B-ALL) was submitted to the Medicine and Healthcare products Regulatory Authority (MHRA) in the UK at the end of July 2024. The MAA review process continues with the European Medicines Agency (EMA) Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press releaseLONDON, Aug. 08, 2024 (GLOBE...

Martin Marietta Reports Second-Quarter 2024 Results

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

Record Second-Quarter Aggregates Gross Profit Per Ton With Pricing Gains Across All Product Lines Closing and Integration of Blue Water Acquisition Reinforces Aggregates-Led Business Model Revised Full-Year Guidance RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Martin Marietta Materials, Inc. (NYSE: MLM) (“Martin Marietta” or the “Company”), a leading national supplier of aggregates and heavy building materials, today reported results for the second quarter ended June 30, 2024. Second-Quarter Highlights (Financial highlights are for continuing operations) Quarter Ended June 30,(In millions, except per share and per ton) 2024 2023 % ChangeRevenues1 $ 1,764 $ 1,821 (3)%Gross profit2 $ 517 $ 560 (8)%Earnings from operations3 $ 398 $ 463 (14)%Net earnings from continuing operations...

YieldMax™ Launches Option Income Strategy ETF on Alibaba (BABA)

Written by Customer Service on August 8, 2024. Posted in Dividend Reports And Estimates.

CHICAGO and MILWAUKEE and NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) — YieldMax™ announced the launch today of the following ETF: YieldMax™ BABA Option Income Strategy ETF (NYSE Arca: BABO) BABO seeks to generate monthly income by pursuing options-based strategies on the ADRs of Alibaba Group Holding Limited (“BABA”). BABO is actively managed by ZEGA Financial. BABO does not invest directly in BABA or its ADRs. BABO is the newest member of the YieldMax™ ETF family and like all YieldMax™ ETFs, aims to deliver current income to investors. Please see table below for distribution and yield information for all outstanding YieldMax™ ETFs. Note: CRSH, FIAT and DIPS are hereinafter referred to as the “Short ETFs” and “ADR” stands for American Depositary Receipt. Please note that distributions may include...

Brookfield Wealth Solutions Announces Second Quarter Results and Declares Regular Quarterly Distribution

Written by Customer Service on August 8, 2024. Posted in Dividend Reports And Estimates.

BROOKFIELD, NEWS, Aug. 08, 2024 (GLOBE NEWSWIRE) — Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A), soon to be renamed ‘Brookfield Wealth Solutions,’ today announced financial results for the quarter ended June 30, 2024. Sachin Shah, CEO, stated, “We delivered strong operating results during the second quarter. With the closing of American Equity Life our asset base has doubled, our annuity sales are growing and we are well positioned for our next stage of growth.”UnauditedAs of and for the periods ended June 30(US$ millions, except per share amounts) Three Months Ended Six Months Ended 2024 2023 2024 2023Total assets $ 130,533 $ 47,994 $ 130,533 $ 47,994Adjusted equity1 11,384 5,047 11,384 5,047Distributable operating earnings1 298 160 577 305Net income 269 360 606 267Net...

Gray Announces Operating Results for the Second Quarter

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray Media,” “Gray,” “we,” “us” or “our”) (NYSE: GTN) today announced financial results for the second quarter ended June 30, 2024, including total revenue of $826 million and total operating expenses (before depreciation, amortization and loss on disposal of assets) of $607 million. While we are overall pleased with our results in the second quarter, macro-economic and other factors largely beyond our control appear likely to result in somewhat lower revenues for the year than we previously anticipated. Our core advertising revenue in the second quarter was $373 million, which was slightly below the low end of our guidance range. For the quarter ending September 30, 2024, we expect core advertising revenue will be flat to up low single digit percentages compared...

Month: August 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals